Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma

Dirk Rades, Stefan Huttenlocher, Niklas Gebauer, Dagmar Hornung, Ngo Thuy Trang, Mai Trong Khoa, Steven E. Schild

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Aim: Renal cell carcinoma (RCC) is a relatively radioresistant tumor and may require for higher radiation doses than other tumor types. Patients and Methods: Nineteen patients treated with 20 Gy of stereotactic radiosurgery (SRS) alone for one to three cerebral metastases were compared to nine patients treated with 16-18 Gy. Results: SRS with 20 Gy led to significantly better local control than did 16-18 Gy (81% vs. 50% at 12 months; p<0.001). Results were also significant on multivariate analysis (risk ratio: 6.30; p=0.033). SRS dose did not associate with freedom from new cerebral metastases (75% vs. 62% at 12 months; p=0.42) or survival (16% vs. 56% at 12 months; p=0.46). On multivariate analyses, better survival was associated with higher Karnofsky performance score (p<0.001) and absence of extracranial metastatic disease (p=0.006). Conclusion: In patients treated with SRS alone, local control of cerebral metastases from RCC was better after 20 Gy than after 16-18 Gy.

Original languageEnglish (US)
Pages (from-to)3571-3574
Number of pages4
JournalAnticancer Research
Volume35
Issue number6
StatePublished - Jun 1 2015

Keywords

  • Cerebral metastases
  • Freedom from new cerebral metastases
  • Local control
  • Renal cell carcinoma
  • Stereotactic radiosurgery
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Rades, D., Huttenlocher, S., Gebauer, N., Hornung, D., Trang, N. T., Khoa, M. T., & Schild, S. E. (2015). Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma. Anticancer Research, 35(6), 3571-3574.